• Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer

    Perioperative Apalutamide Improves Outcomes in High-Risk Localized Prostate Cancer
    Originally published by our sister publication Clinical Oncology NewsCHICAGO—Adding perioperative apalutamide (Erleada, Johnson & Johnson) to androgen deprivation therapy (ADT) delays the risk for metastasis or death and significantly improves pathologic response rates in patients with high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy, according to the phase 3 PROTEUS trial.Investigators said the results, which were presented at the 2026 American
  • FDA Finalizes Guidance to Broaden Cancer Trial Eligibility

    FDA Finalizes Guidance to Broaden Cancer Trial Eligibility
    By Jennifer KulpaThe FDA has finalized three guidance documents urging sponsors to ease overly restrictive eligibility criteria in cancer clinical trials. The recommendations address performance status, washout periods and concomitant medications, and laboratory values, potentially expanding enrollment to more patients treated in ambulatory settings.Issued in July 2026 by the FDA’s Oncology Center of Excellence, Center for Drug Evaluation and Research, and Center for Biologics Evaluation a

Follow @newsl_pharmacy on Twitter!